Source-grounded facts extracted from Clearside Biomedical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Clearside Biomedical, Inc. entered chapter 11 in United States Court for the District of Delaware.
“the Company filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11 of the Bankruptcy Code in the United States Court for the District of Delaware”
Clearside Biomedical, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2025-11-23).
“On November 23, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court ” and such case, the “ Case ”).”
Clearside Biomedical, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).
“August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securities of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing that certain MVLS Notice. Trading of the Common Stock will be suspended at the opening of”
Clearside Biomedical, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
“November 24, 2025, the Company received written notice (the “ Delisting Notice ”) from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Case and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), will be delisted from Nasdaq. In addition, as previously disclosed, on August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with t”
Clearside Biomedical, Inc.: Clearside Biomedical filed a Certificate of Amendment to effect a 1-for-15 reverse stock split and reduce authorized common shares from 400,000,000 to 26,666,666 (effective 2025-09-12).
“On September 10, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the “ Shares Reduction ”).”
Clearside Biomedical, Inc.: Filed a Certificate of Amendment to effect a 1-for-15 reverse stock split and reduce authorized shares from 400,000,000 to 26,666,666 (effective 2025-09-12).
“On September 10, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the “ Shares Reduction ”). The Amendment will be effective at 5:00 p.m. Eastern Time on September 12, 2025.”
Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“August 28, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with the minimum Market Value of Listed Securities (“ MVLS ”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Requirement ”). The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c”
Clearside Biomedical, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
“previously disclosed, on February 7, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). As the Company did not regain compliance with the Minimum Bid Pric”
Clearside Biomedical, Inc. announced a restructuring with charges of approximately $3.4 million for severance and other employee termination-related costs affecting the Company (all Clearside employees).
“On July 17, 2025, Clearside Biomedical, Inc. (the “ Company ”) announced that it is exploring strategic alternatives to enhance shareholder value, and that in connection with such process and in order to extend the Company’s resources, the Company is implementing a plan pursuant to which all Clearside employees will have their employment with the Company terminated and will transition into consulting roles with the Company. The reduction in force is expected to be completed during the third quarter of 2025. The Company estimates that it will incur charges of approximately $3.4 million for severance and other employee termination-related costs in the third quarter of 2025.”
Clearside Biomedical, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2025-05-30).
“the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000”
Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“February 7, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5”
Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 7, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common”
Clearside Biomedical, Inc. reported first quarter ended March 31, 2024 results: revenue $230,000, net income $11.8 million, EPS $0.17 per share of common stock.
“by delivering drug directly to the back of the eye via the SCS Microinjector. First Quarter 2024 Financial Results • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023. • Research and development expenses for the first quarter of 2024 were $5.6 million, compared to $4.5 million for the first”
Anthony S. Gibney was appointed as Director at Clearside Biomedical, Inc..
“On April 15, 2024, the Board of Directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Anthony S. Gibney to serve as a director of the Company.”
Clearside Biomedical, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $6.3 million, net income Net loss for the fourth quarter of 2023 was $4.8 million, EPS $0.08 per share.
“the first patient in the CoMpass trial in December 2023. Fourth Quarter 2023 Financial Results • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022. The $6.0 million increase was primarily attributable to the receipt of $5.0 million in an upfront license fee from”
Clearside Biomedical, Inc. entered into Placement Agency Agreement with Citizens JMP Securities, LLC (effective 2024-02-06).
“Citizens JMP Securities, LLC acted as the placement agent (the “Placement Agent”) in connection with the Registered Direct Offering pursuant to the Placement Agency Agreement, dated February 6, 2024 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent.”
Clearside Biomedical, Inc. entered into Purchase Agreement with institutional investors and an existing stockholder valued at approximately $15.0 million (effective 2024-02-06).
“On February 6, 2024, Clearside Biomedical, Inc. (“Clearside” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors and an existing stockholder, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Direct Offering”): (i) an aggregate of 11,111,111 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share; and (ii) warrants to purchase up to 11,111,111 shares of Common Stock (the “Warrants”).”
Clearside Biomedical, Inc. amended License Agreement with Emory University valued at reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li (effective 2024-01-31).
“On January 31, 2024 (the “ Amendment Execution Date ”), Clearside Biomedical, Inc. (the “ Company ”), Emory University (“ Emory ”) and Georgia Tech Research Corporation (together with Emory, the “ Licensor ”), entered into an amendment (the “ Amendment ”) to the Company’s License Agreement with Licensor dated July 4, 2012 (as amended, the “ License Agreement ”), pursuant to which the Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector.”
Clearside Biomedical, Inc. amended Letter Agreement with Healthcare Royalty Partners IV, L.P., HCR Clearside SPV, LLC valued at $12.5 million milestone payment (effective 2023-12-22).
“On December 22, 2023, Clearside Biomedical, Inc., through its wholly owned subsidiary Clearside Royalty LLC (" Royalty Sub "), entered into a letter agreement (the " Letter Agreement ") with Healthcare Royalty Partners IV, L.P. (" HCR ") and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC) (" Agent ") amending that certain Purchase and Sale Agreement, dated as of August 8, 2022 (the " Purchase Agreement "), by and among Royalty Sub, HCR and Agent.”
Clearside Biomedical, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 13, 2023, Clearside Biomedical, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended September 30, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.”
Clearside Biomedical, Inc. entered into License Agreement with BioCryst Pharmaceuticals, Inc. valued at Upfront license fee of $5.0 million, clinical and regulatory milestones up to $30.0 million, sales-b (effective 2023-11-01).
“On November 1, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a license agreement (the “ License Agreement ”) with BioCryst Pharmaceuticals, Inc. (“ BioCryst ”) pursuant to which the Company granted BioCryst an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and prevention of diabetic macular edema (“ DME ”).”
Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“September 27, 2023, Clearside Biomedical, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 25, 2024, to regain complia”
Clearside Biomedical, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million.
“input on the Company’s research and development programs. Second Quarter 2023 Financial Results • License Revenue: License and other revenue for the second quarter of 2023 was $1.0 million, compared to $0.4 million for the second quarter of 2022. • Cost of Goods Sold: Cost of Goods Sold for the second quarter of 2023 was $0.2 million, compared to $0 for the second”
Clearside Biomedical, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-22 meeting.
“Proposal No. 3 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 40,223,369 118,934 344,773”
Clearside Biomedical, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. at the 2023-06-22 meeting.
“Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation paid to the named executive officers 21,869,683 1,039,147 2,296,897 Broker Non-Votes: 15,481,349.”
Clearside Biomedical, Inc. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-22 meeting.
“Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Jeffrey L. Edwards 21,010,493 4,195,234 Clay B. Thorp 21,038,323 4,167,404 Benjamin R. Yerxa 22,824,670 2,381,057 Broker Non-Votes: 15,481,349. All nominees were elected.”
Clearside Biomedical, Inc. terminated Sales Agreement dated June 30, 2017 with Cowen and Company, LLC with Cowen and Company, LLC valued at terminated (effective 2023-05-12).
“On May 12, 2023, the Company and Cowen and Company, LLC (“ Cowen ”) agreed to terminate the Sales Agreement, dated as of June 30, 2017, (the “ Prior Sales Agreement ”) between the Company and Cowen, effective as of May 12, 2023 (the “ Termination Date ”).”
Clearside Biomedical, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $50 million (effective 2023-05-12).
“On May 12, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a Controlled Equity Offering SM Sales Agreement (the “ Agreement ”) with Cantor Fitzgerald & Co. (“ Cantor ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Common Stock ”), having an aggregate offering price of up to $50 million through or to Cantor as its sales agent or principal.”
Clearside Biomedical, Inc. reported the first quarter ended March 31, 2023 results: revenue $4,000, net income $9.3 million, EPS $0.15 per share.
“First Quarter 2023 Financial Results • License Revenue: Clearside’s license and other revenue for the first quarter of 2023 was $4,000, compared to $347,000 for the first quarter of 2022. • Research and Development (R&D) Expenses : R&D expenses for the first quarter of 2023 and the first quarter of 2002 were $4.5 million. • General and Administrative (G&A) Expenses : G&A expenses for the first quarter of 2023 were $3.2 million, compared to $3.5 million for the first quarter of 2022. • Other Income: Other income for the first quarter of 2023 was $492,000, compared to $2,000 for the first quarter of 2022. Other income in both periods was comprised of interest income from cash and cash equivalents. • Other Expense : Non-cash interest expense for the first quarter of 2023 was $2.2 million, compared to $0 in the first quarter of 2022. Non-cash interest expense was comprised of imputed interest on the liability related to the sales of future royalties and the amortization of the associated i”
Clearside Biomedical, Inc. reported Year ended December 31, 2022 results: revenue $1.3 million, net income Net loss of $32.9 million, EPS $0.55 per share.
“Clearside’s license and other revenue for the year ended December 31, 2022, was $1.3 million, compared to $29.6 million for the year ended December 31, 2021. The $28.2 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in 2021. Cost of goods sold for the year ended December 31, 2022, was $204,000, compared to $0 for the year ended December 31, 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the year ended December 31, 2022, were $19.6 million, compared to $18.5 million for the year ended December 31, 2021. The $1.1 million increase was primarily attributable to CLS-AX program costs. General and administrative expenses for the year ended December 31, 2022, were $11.8 million, compared to $11.7 million for the year ended December 31, 2021. Net loss for the year ended December 31, 2022, was $32.9 million, or $0.55 per share of common stock, compared to net incom”
Clearside Biomedical, Inc. reported Fourth quarter 2022 results: revenue $330,000, net income Net loss of $9.7 million, EPS $0.16 per share.
“Clearside’s license and other revenue for the fourth quarter of 2022 was $330,000, compared to $25.7 million for the fourth quarter of 2021. The $25.4 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in the fourth quarter of 2021. Cost of goods sold for the fourth quarter of 2022 was $204,000, compared to $0 for the fourth quarter of 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the fourth quarter of 2022 were $5.0 million, compared to $3.8 million for the fourth quarter of 2021. The $1.2 million increase was primarily attributable to preclinical research program costs. General and administrative expenses for the fourth quarter of 2022 were $3.2 million, compared to $3.1 million for the fourth quarter of 2021. Net loss for the fourth quarter of 2022 was $9.7 million, or $0.16 per share of common stock, compared to net income of $18.7 million, or $0.31 per”
Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..
“Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023”
Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..
“On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023”
Clearside Biomedical, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.3 million, net income $7.8 million, EPS $0.13 per share of common stock.
“Clearside’s license and other revenue for the third quarter of 2022 was $0.3 million”
Benjamin Yerxa was appointed as director at Clearside Biomedical, Inc..
“the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.